TL;DR: Altay Therapeutics is a Y Combinator Winter 2020 startup Altay develops disease-modifying therapies targeting transcription…, currently active with a team of 6.
Altay develops disease-modifying therapies targeting transcription…
Last verified:
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, b…
Built by LemStudio
Yes. Altay Therapeutics was funded by Y Combinator in the Winter 2020 batch. Altay develops disease-modifying therapies targeting transcription…
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already…
Altay Therapeutics was part of Y Combinator's Winter 2020 batch.
Altay Therapeutics has a team of 6 people according to Y Combinator's directory.
Altay Therapeutics is currently listed as Active with a team of 6 in Y Combinator's directory.
Loading interactive view…